![]() ![]() In this study we assessed the impact of PCI on health-related quality of life (HRQoL). The NVALT-11/DLCRG-02 phase III trial ( identifier: NCT01282437) showed that, after standard curative intent treatment, prophylactic cranial irradiation (PCI) decreased the incidence of symptomatic brain metastases (BM) in stage III non-small cell lung cancer (NSCLC) patients compared to observation. 17 Maastricht University Medical Centre(+), Department of Radiation Oncology (Maastro Clinic), GROW School of Oncology and Developmental Biology, The Netherlands KU Leuven, Radiation Oncology, Belgium.16 University of Groningen and University Medical Center Groningen, Department of Pulmonary Diseases, The Netherlands.15 Netherlands Cancer Institute (NKI), Department of Biometrics, Amsterdam, The Netherlands.14 Netherlands Cancer Institute (NKI), Department of Pulmonology, Amsterdam, The Netherlands.13 Isala Hospital, Department of Pulmonology, Zwolle, The Netherlands.12 University Medical Center Utrecht, Department of Radiation Oncology, The Netherlands.11 Free University Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands.10 University of Groningen, University Medical Center Groningen, Department of Radiation Oncology, The Netherlands.9 Medical Center Alkmaar, Department of Pulmonology, The Netherlands.8 Antonius Hospital Nieuwegein, Department of Pulmonology, The Netherlands.7 Radiotherapy Institute Arnhem, Arnhem, The Netherlands.6 Netherlands Cancer Institute (NKI), Department of Radiation Oncology, Amsterdam, The Netherlands.5 Erasmus University Medical Center, Department of Radiation Oncology, Rotterdam, The Netherlands.4 Maastricht University Medical Center(+), Department of Pulmonology, GROW Research Institute, The Netherlands.3 Maastricht University Medical Centre(+), Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, The Netherlands Care and Public Health Research Institute (CAPHRI), Maastricht University, The Netherlands.Electronic address: 2 Maastricht University Medical Centre(+), Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, The Netherlands. 1 Maastricht University Medical Centre(+), Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, The Netherlands.Interview conducted by Victoria Jones.įilmed as a highlight of ERS 2021 (Virtual). Support: Interview and filming supported by Touch Medical Media. Presentation slides shared with permission from the author. What are the implications of this study for patients with NSCLC and future research? (4:20)ĭisclosures: Rolof Gijtenbeek has nothing to disclose in relation to this video.How did patients respond in terms of efficacy and safety in the NVALT 17 study? (3:45).Please can you outline the key methodology used in the NVALT 17 study? (2:30).What evidence already existed on the effect of combining EGFR tyrosine kinase inhibitors and chemotherapy in NSCLC? (1:15).EGFR tyrosine kinase inhibitors such as erlotinib are indicated in the treatment of EGFR mutated non-small cell lung cancer (NSCLC) – what are the current challenges with treatment? (0:12).We were delighted to talk with Dr Rolof Gijtenbeek (Medical Center Leeuwarden, Leeuwarden, The Netherlands) around his abstract on ‘ Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.‘, (Presentation ID 4324) which was presented at ERS International Congress 2021, 5-8 September 2021. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |